Behavioral Intervention and Anti-Obesity Drug Therapy.
- Author:
Mee Kyoung KIM
1
Author Information
1. Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. makung@catholic.ac.kr
- Publication Type:Review
- Keywords:
Obesity;
Behavioral intervention;
Anti-obesity drug
- MeSH:
Adult;
Advisory Committees;
Anti-Obesity Agents;
Benzazepines;
Blood Glucose;
Body Mass Index;
Cardiovascular Diseases;
Diethylpropion;
Fructose;
Humans;
Incidence;
Korea;
Lactones;
Life Expectancy;
Mass Screening;
Mazindol;
Morpholines;
Obesity;
Phentermine;
Risk Factors;
United States Food and Drug Administration;
Weight Loss
- From:Korean Journal of Medicine
2013;84(5):624-628
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. The U.S. Preventive Service Task Force (USPSTF) recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions. Behavioral interventions can lead to a moderate weight loss and improvement in blood sugar and other risk factors for cardiovascular disease. Behavioral interventions decreased the incidence of diabetes diagnosis by about 50% over 2 to 3 years. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. The U.S. Food and Drug Administration approved lorcaserin and phentermine plus topiramate combination for treatment of obesity in 2012.
